Literature DB >> 12652379

Emerging bone problems in patients infected with human immunodeficiency virus.

Kristin Mondy1, Pablo Tebas.   

Abstract

Recently, a high incidence of osteopenia and osteoporosis has been observed in individuals infected with human immunodeficiency virus (HIV). This problem appears to be more frequent in patients receiving potent antiretroviral therapy. Other bone-related complications in HIV-infected individuals, including avascular necrosis of the hip and compression fracture of the lumbar spine, have also been reported. People living with HIV have significant alterations in bone metabolism, regardless of whether they are receiving potent antiretroviral therapy. The underlying mechanisms to account for these observations remain unknown, although studies are underway to examine the relationship between the bone abnormalities and other complications associated with HIV and antiretroviral therapy. HIV-infected patients with osteopenia or osteoporosis should be treated similarly to HIV-seronegative patients with appropriate use of nutritional supplements (calcium and vitamin D) and exercise. Hormone replacement and antiresorptive therapies might be also indicated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12652379     DOI: 10.1086/367566

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  23 in total

1.  Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy.

Authors:  Gayatri Mirani; Paige L Williams; Miriam Chernoff; Mark J Abzug; Myron J Levin; George R Seage; James M Oleske; Murli U Purswani; Rohan Hazra; Shirley Traite; Bonnie Zimmer; Russell B Van Dyke
Journal:  Clin Infect Dis       Date:  2015-08-12       Impact factor: 9.079

2.  Avascular necrosis of the femoral head in HIV positive patients-an assessment of risk factors and early response to surgical treatment.

Authors:  L Chokotho; W J Harrison; N Lubega; N C Mkandawire
Journal:  Malawi Med J       Date:  2013-06       Impact factor: 0.875

3.  Prevalence of abnormal bone mineral density in hiv-positive patients in ibadan, Nigeria.

Authors:  T O Alonge; V N Okoje-Adesomoju; O M Atalabi; H A Obamuyide; D Olaleye; I F Adewole
Journal:  J West Afr Coll Surg       Date:  2013 Oct-Dec

Review 4.  Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS.

Authors:  George Pan; Zhen Yang; Scott W Ballinger; Jay M McDonald
Journal:  Ann N Y Acad Sci       Date:  2006-04       Impact factor: 5.691

5.  Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors.

Authors:  George Pan; Michael Kilby; Jay M McDonald
Journal:  AIDS Res Hum Retroviruses       Date:  2006-11       Impact factor: 2.205

Review 6.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

Review 7.  Hormonal contraception and HIV-positive women: metabolic concerns and management strategies.

Authors:  Julie Womack; Susan Richman; Phyllis C Tien; Margaret Grey; Ann Williams
Journal:  J Midwifery Womens Health       Date:  2008 Jul-Aug       Impact factor: 2.388

8.  Impact of age on markers of HIV-1 disease.

Authors:  Vanessa Pirrone; David J Libon; Christian Sell; Chad A Lerner; Michael R Nonnemacher; Brian Wigdahl
Journal:  Future Virol       Date:  2013-01       Impact factor: 1.831

Review 9.  Fracture management in HIV positive individuals: a systematic review.

Authors:  Maheshi P C Wijesekera; Simon Matthew Graham; David Griffith Lalloo; Hamish Simpson; William J Harrison
Journal:  Int Orthop       Date:  2016-09-21       Impact factor: 3.075

10.  The Relationship Between HIV Infection and Cardiovascular Disease.

Authors:  Birgitt Dau; Mark Holodniy
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.